Medications

US company withdraws ALS drug after it fails in trial

Amylyx Pharmaceuticals announced Thursday it was withdrawing its approved treatment against the deadly neurodegenerative disease ALS after clinical data found no evidence the drug worked.

Oncology & Cancer

Exploring ferroptosis and its implications in lung cancer

An estimated 2.2 million people suffer from lung cancer worldwide, making it the second most common type of cancer. Though improvements in treatment have been made, the overall survival rate of lung cancer patients is low, ...

page 6 from 14